statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential...

Precigen's Annual Meeting Decisions and Director Departure

Precigen (PGEN) just unveiled an announcement. At Precigen, Inc.'s 2024 Annual Meeting, stockholders voted to expand the 2023 Omnibus Incentive Pla...

6 Analysts Assess Precigen: What You Need To Know

Latest Ratings for PGEN
 DateFirmActionFromTo Feb 2021StifelInitiates Coverage OnBuy Feb 2021Wells FargoInitiates Coverage OnOverweight Dec 2020HC Wainwright & Co.MaintainsBuy
 View More Analyst...

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response Precigen...

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting Precigen to Host a Webcast on...

Precigen Reports First Quarter 2024 Financial Results and Business Updates

Precigen Reports First Quarter 2024 Financial Results and Business Updates Precigen Reports First Quarter 2024 Financial Results and Business Updates PR Newswire GERMANTOWN, Md., May 14, 2024 Pivotal...

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual...

Precigen adds to disease awareness calendar with day dedicated to recurrent respiratory papillomatosis

Precigen adds to disease awareness calendar with day dedicated to recurrent respiratory papillomatosis
apark
Fri, 03/29/2024 - 10:48...

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold...

Precigen participates in a conference call with Cantor Fitzgerald

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Volume	568,754.00
52-Wk High	$1.93
52-Wk Low	$0.8354

PGEN Precigen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals